Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
BICTF stock price ended at $0.01 on 星期三, after rising Infinity%
On the latest trading day May 14, 2025, the stock price of BICTF rose by Infinity%, climbing from $0.01 to $0.01. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.01 and a high of $0.01. Notably, trading volume dropped by 38.7K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 39.0K shares were traded, equating to a market value of approximately $202.0K.